MedTrace Logo

XIENCE V Everolimus Eluting Coronary Stent System (EECSS) China: Post-Approval, Single-Arm Study

NCT01249027 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 2605

Last updated 2019-03-01

Study results available
· View outcomes & findings →

Summary

This is a prospective, observational, single-arm, open-label, multicenter, postapproval registry study in China. The purpose of this study is to:

* Evaluate the continued safety and effectiveness of the XIENCE V EECSS in a cohort of real-world patients receiving the XIENCE V EECSS during commercial use
* Evaluate patient compliance to dual antiplatelet therapy (DAPT)

Conditions

  • Angioplasty
  • Chronic Coronary Occlusion
  • Stent Thrombosis
  • Vascular Disease
  • Myocardial Ischemia
  • Coronary Artery Stenosis
  • Coronary Disease
  • Coronary Artery Disease
  • Coronary Restenosis

Interventions

DEVICE

XIENCE V® Everolimus Eluting Coronary Stent System (EECSS)

Patients who receive XIENCE V® Everolimus Eluting Coronary Stent System (EECSS)will be invited to participate in the study.

Sponsors & Collaborators

  • Abbott Medical Devices

    lead INDUSTRY

Principal Investigators

  • Junbo Ge, MB, MSc, MD, FACC, FESC, FSCAI · Fudan University

  • Jiyan Chen, MD · Institute of Cardiovascular Guangdong, Guangdong Provincial People's Hospital

  • YuJie Zhou, MD, Ph.D · An Zhen Hospital

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-11-30
Primary Completion
2016-12-31
Completion
2017-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01249027 on ClinicalTrials.gov